Articles On Recce Pharmaceuticals (ASX:RCE)

Synthetic anti-infectives company Recce Pharmaceuticals (ASX:RCE) has announced it has recruited the first cohort of 10 healthy male subjects in its Phase I intravenous clinical trial of its lead compound.

R327 is administered as a single dose via a 1-hour IV infusion at a uniform rate, with all 80 subjects anticipated to have been dosed by the end of H1 2022.

Synthetic anti-infective company Recce Pharmaceuticals (ASX:RCE) has provided an update on its Phase I/II clinical trial for the treatment of burn wound infections.

Recce Pharmaceuticals’ share price has been boosted this morning on positive news about one of its drugs working on Perth patients with infected burns wounds.

“This initial update builds upon strong pre-clinical data demonstrating fast and efficient killing activity against common and problematic bacterial strains, and we are excited for the potential of R327 in the clinic," says CEO.

The ASX 200 Health Index (XHJ) is down by 0.80% at the time of writing, compared to the broader index which is down by 0.40%. The stock price of Neuren Pharmaceuticals (ASX:NEU) is up 100% this morning after the company announced its North...

Recce Pharmaceuticals (RCE) provides an update in the clinical trial of RECCE 327 (R327) for the treatment of burn wound infections RCE reports broad spectrum antibiotic activity on bacterial burn wound infections with a visible infection...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is soaring today. This comes after the pharmaceutical company provided an update on its clinical trial for the treatment of burn wound infections. At the time of writing, the Recce share...

In October, the Chinese government released its intellectual proprietary (IP) patents strategy paper, listing its main goals for the next five years. Part of that plan is to double the foreign “high value” patents from the current 40,000 to...

In March this year, Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.

Receiving human ethics approval is a momentous achievement for Recce and the clinicians seeking effective treatments to combat antibiotic-resistant bacteria,” says chairman.

Recce Pharmaceuticals (RCE) has received Human Research Ethics Committee (HREC) approval to begin its phase one intravenous (IV) trial of RECCE327 (R327) The phase one trial is a randomised, placebo-controlled, ascending-dose, single-dose...

The ASX 200 Health Index (XHJ) is up by 0.80% at the time of writing, compared to the broader index which is higher by 0.7%. Notices from both the Australian and European Patent Offices have been received by Noxopharm (ASX:NOX), relating to...

The misuse and overuse of antibiotics have led to the rapid growth of superbugs – a type of bacteria resistant to conventional treatments Serious infections such as pneumonia, tuberculosis and salmonella are becoming difficult to treat as...

The ASX retreated again as angst over inflation and the withdrawal of stimulus continued to weigh on global markets. The ASX 200 closed at 7,300 – 0.28% lower than Friday’s close. Tech was the biggest laggard, losing nearly 3% but energy an...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price was halted today after the company made a key announcement. Recce shares were trading 1.61% lower at 91.5 cents before being placed into a trading halt. Let’s get into the thick of it t...

The ASX had a positive end to the week with the ASX 200 gaining 0.87% today taking its weekly gain to 1.9%. All sectors gained with the best being resources which gained nearly 1.7%. Australia’s rise was in line with the broader Asia-Pacifi...

Superbugs that are resistant to antibiotics are causing an urgent global health crisis, but Recce Pharmaceuticals believes it has the solution.

Summary Northern Star (ASX:NST) reports strong June quarter, shares move up Santos (ASX:STO) jumps most in one month on lifting production, sales outlook Orocobre hits record high as lithium demand boosts production, pricing The S...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price ended the day higher after the company secured a patent in the United States. At the closing bell, the pharmaceutical company’s shares finished the day up 3.27% to $1.10. Let’s take a cl...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

The Aussie share market has fallen for two consecutive days, down by 0.46% today. Seven sectors were down, while four rose. Utilities and Mining were the worst peforming sectors, while Healtcare and IT were the best. In big cap news today,...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is on the move today. It comes after the pharmaceutical company provided a patent update on its synthetic anti-infectives. At the time of writing, the Recce share price is up 5.73% to $1...

RECCE® 327 (R327) has been shown to reduce deadly flesh-eating bacterial count below limit of quantification within 24 hours, at varying concentrations.

The Australian share market has followed Wall Street’s lead, closing 0.85% lower in today’s trading. All sectors were down except for Health Care, with the worst performers being Energy and Mining, both falling by more than 2%. In big cap n...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is falling after the company released an update on its clinical pipeline. In afternoon trade, shares in Recce Pharmaceuticals are trading 0.46% lower at $1.08. The update announced delay...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price has been a strong performer on Thursday. In afternoon trade, the biotechnology company’s shares are up 8.5% to $1.13. Why is the Recce share price surging higher? Investors have been bid...

Recce Pharmaceuticals (ASX:RCE), a company developing new classes of synthetic anti-infectives, has announced further results for its R327.

Following encouraging test results from stage1A and stage1B, RECCE® R327 received a qualified recommendation to advance to stage 2 of the program for further testing to be conducted by CSIRO.

The market is trading near day’s high at the close, after the Reserve Bank of Australia’s (RBA) maintained status quo in its latest policy announcement and upgraded the country’s GDP growth estimates. The benchmark index ASX 200 was up 35.5...

Summary Digital health player ResApp Health has entered into a non-exclusive distribution agreement with Ilara Health. Recce Pharmaceuticals stated that RECCE® 327 had shown bactericidal activity against ESKAPE pathogens, including the...

The Australian share market continued to trade in positive on Tuesday afternoon, owing to favourable global cues, with the benchmark index ASX 200 adding 21.9 points or 0.31% to trade at 7,050. Seven of 11 sectors were trading in green, wh...

ASX biotechs Recce Pharmaceuticals (ASX:RCE) and Botanix Pharmaceuticals (ASX:BOT) have this morning both given updates on their antimicrobial drug candidates as interest heats up on weapons to combat so-called “superbugs”. Recce said its s...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price has been a positive performer on Tuesday. In morning trade, the pharmaceutical company’s shares are up 3.5% to $1.17. This latest gain means the Recce Pharmaceuticals share price has now...

Recce Pharmaceuticals (ASX:RCE) has announced that its RECCE 327 has demonstrated bactericidal activity against all six antibiotic-resistant ESKAPE pathogens, including drug-resistant mutations as well as two additional WHO priority...

Mixed start to the month on Wall Street Wall Street was mixed, with the Dow Jones and S&P500 indices rising by 0.70% and 0.275 respectively, while tech heavy NASDAQ was down by 0.48%. Broadly speaking, investors ditched technology, fina...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is slipping today after the company released its quarterly activities report. At the time of writing, the Recce share price is down 1.85% to $1.06 per share. Recce is a drug discovery a...

15 Apr 2021 - Recce Pharmaceticals’ (ASX:RCE) lead compound RECCE® 327 has been registered in the Australian New Zealand Clinical Trial Registry (ANZCTR) for its Phase I/II Topical…

Recce Pharmaceuticals Ltd (ASX: RCE) shares are on the move in mid-afternoon trade. This comes after the company announced the inclusion of Recce 327 into the Australian New Zealand Clinical Trial Registry (ANZCTR). At the time of writing,...

The first person formally treated with Recce Pharmaceutical’s (ASX:RCE) next-generation antibiotic calls it a “bloody miracle” after it cured a chronic, debilitating sinus infection he had suffered from for decades. Fletcher, a 59-year-old...

Recce Pharmaceuticals (ASX:RCE) has announced that a SAS Category A notification has been made to the TGA by a medical practitioner following the successful treatment of a patient with RECCE 327.

The Recce Pharmaceuticals Ltd (ASX: RCE) share price rose 7% this morning after the company shared good news of its drug, RECCE 327 (R327). The gains come on the back of the successful treatment of a terminally ill human with the antivirus...

Apr 2021 - Superbug and viral pathogen treatment developer Recce Pharmacetical (ASX:RCE)’s unapproved drug R327 has successfully saved a patient suffering a life-threatening illnes…

In late morning trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another decent gain. At the time of writing, the benchmark index is up 0.5% to 6,919.6 points. Four ASX shares that are climbing more than most today are li...

Recce Pharmaceuticals Ltd [ASX:RCE] is a prime example. With the stock trading 0.5% lower at time of writing. Suffering a mixed day of trading as its share price has jumped up and down... The post Recce Pharmaceuticals Shares Up on Positive...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price has spent today in the red despite the company releasing positive data from anti-infective drug trials against bacterial sinusitis in mice. It seems shareholders weren’t excited by the r...

Source:Guschenkova, Shutterstock Summary Recce Pharmaceutical disclosed that data from an animal study demonstrated the positive efficacy of its new anti-infective formulation RECCE® 111. The Company’s R327 and R111 compounds showed s...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is pushing higher on Monday morning. At the time of writing, the synthetic anti-infectives focused biotechnology company’s shares are up 3% to $1.01. Why is the Recce share price pushing...

Source: Shutterstock Summary ASX-listed world-leader in synthetic-polymer antibiotics Recce Pharmaceuticals to list its stocks on the FSE. The listing will broaden the investor base and enable access to additional capital markets. Re...